Hengrui, CSPC, Qilu and others take the lead in fighting the "new drug war", and medical innovation blossoms at multiple levels

 China's pharmaceutical innovation is blooming at multiple levels, and strive to stand on the international stage to carry out PK
.
Among them, the traditional pharmaceutical giants represented by Hengrui, CSPC, and Qilu are forming a stormtrooper to win the "new drug war", while the new and cutting-edge teams represented by Baekje and Cinda are also advancing at a rapid pace to the new heights
.
The "New Drug War" stormtrooper represented by Hengrui, CSPC, and Qilu Hengrui is a company that attaches great importance to R&D investment among many domestic pharmaceutical companies.
Data shows that its R&D expenditure in 2020 is 4.
989 billion yuan in the first three quarters of this year.
R&D expenditures were 4.
141 billion yuan
.
In the past five years, research and development expenses have increased year by year.
From 2017 to the third quarter of 2021, the proportion of research and development has increased from 12.
71% to 20.
51%
.
It is understood that in recent years, Hengrui has successively undertaken 57 special projects of "National Major New Drug Development", 23 national key new product projects and dozens of provincial science and technology projects
.
In terms of the development of innovative drugs, Hengrui has basically formed a positive development trend of innovative drugs being applied for clinical trials every year, and innovative drugs are on the market every 1-2 years
.
Nowadays, the innovative drugs are irecoxib, apatinib mesylate, thiopefigrastim, pyrrotinib maleate, carrelizumab, remazolam tosylate, and fluzoparib.
Approved for listing
.
In addition, on November 8th, Hengrui received new news about its innovative drug.
Its innovatively developed SHR-1701 injection was approved for clinical trials, and the drug was also undergoing phase 1 clinical trials in Australia
.
It is reported that the drug is mainly suitable for advanced malignant tumors, and there is no similar product on the market at home and abroad
.
In terms of R&D, CSPC also has strong R&D strength and technical reserves
.
Statistics show that CSPC has invested more than 1.
6 billion yuan in R&D in the first half of 2021, has 86 national science and technology projects, and won 6 national awards
.
It is understood that CSPC has 5 major R&D centers around the world, has built 8 major technology platforms, has a R&D team of more than 2,000 people, focuses on 6 major therapeutic areas, and has more than 100 innovative drug projects under development.

.
At the same time, CSPC is actively cooperating with domestic and foreign research institutes, universities, clinical centers, and industry associations
.
According to the relevant person in charge of the company, in the future, CSPC will continue to increase R&D investment and R&D team building
.
In the next 5 years, CSPC will have more than 30 innovative drugs on the market, and at the same time, it will actively build an international BD ecosystem
.
In recent years, Qilu Pharmaceutical has been guided by the strategy of “emphasis on imitation and innovation” through self-research and development, international cooperation, project introduction, and university cooperation.
In the research and development of innovative drugs, the barriers have been constantly overcome, and good news have been spread frequently
.
Today, Qilu Pharmaceutical has more than 70 innovative drug research and development product lines that are simultaneously advancing, and more than 10 of them have entered the clinical stage.
It is expected that 2 to 3 innovative drugs will be launched every year after 2022
.
It is understood that the proportion of Qilu Pharmaceutical’s R&D investment has continued to increase in recent years, and the former 5%-8% of sales revenue has rapidly increased to the current 8%-10%
.
From 2017 to 2020, its R&D investment soared from 1.
2 billion yuan to 2.
65 billion yuan, an increase of 2.
2 times
.
In 2021, Qilu Pharmaceutical's R&D investment will account for 11.
8% of sales revenue, reaching 3.
9 billion yuan
.
Innovative drug teams represented by Baekje and Cinda According to the industry, unlike Hengrui, CSPC, and Qilu, the new teams represented by Baekje and Cinda were born to be innovative drugs
.
They are not dragged down by mature products (generic drugs), financing is basically unhindered, surrounded by well-known capital, they have enough funds to invest in research and development, and they are good at rapidly expanding pipelines through cooperation.
The conditions of time and place make them become The sweet pastry of the "new talent market"
.
For example, BeiGene's product pipeline and R&D layout published in August show that it is known as "the new brother of R&D investment", and the company has more than 50 preclinical projects in progress.
It has everything from PROTAC to mRNA and CAR-NK.
According to reports, 11 self-developed drugs have entered the clinical or commercialization stage.

.
From the perspective of company performance, BeiGene Gaoguang is frequently present.
Data shows that its total revenue in the first three quarters of 2021 reached 962.
3 million US dollars, an increase of 361% year-on-year, of which product revenue was approximately US$440 million
.
It is worth noting that in the third quarter of 2021, the global sales of its first new drug BTK inhibitor Zebutinib, which was commercialized globally, was US$65.
8 million, an increase of 320% year-on-year, while domestic sales also increased by 223% year-on-year
.
And Cinda Bio, which has always insisted on building its own commercialization team, is the successful representative of the first batch of commercialized Biotech
.
Its PD-1 sales in the third quarter of 2021 are about 800 million yuan, which is about the total amount of Baiji and Junshi.
This commercialization capability also allows Cinda to attract some domestic Biotech
.
The R&D and global development of innovative drugs are the future direction of Cinda Biotech
.
It is understood that there are currently 26 products in Cinda's biological product pipeline, and 5 of them have entered the commercialization stage
.
Among the commercial products, Daboshu and the dalbotan (pemigatinib, FGFR 1/2/3 inhibitor) approved in the Taiwan market are innovative drugs, and there are three other biosimilar drugs on sale, namely Dayotong.
, Su Lixin, and Dabohua
.
The company's annual R&D expenditure has increased from 200 million to 300 million U.
S.
dollars at the time of listing to approximately 400 million U.
S.
dollars at present.
The company will continue to grow in the future to support the development of new drugs.
The goal is to have good drugs on the market every year or every two years
.